Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Appointed director
CC transcript
Director departure
DURECT CORP (DRRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update - Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in Q4 2023"
07/21/2023 8-K Quarterly results
06/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis Topline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 — DURECT Corporation , a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment in its Phase 2b AHFIRM clinical trial investigating larsucosterol for the treatment of patients with severe alcohol-associated hepatitis , achieving its enrollment target of 300 patients. “We are excited to have reached this critical milestone and look forward to reporting topline data, anticipated in the fourth quarter of 2023,” said James E. Brown, D.V.M., President and Chief Executive Officer of DURECT. &#x2..."
05/16/2023 8-K Investor presentation
Docs: "53,000 0 1 2 3 4 5 6 7 8 9"
05/08/2023 8-K Quarterly results
Docs: "DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update - Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2H 2023"
03/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/07/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update - - Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET - - Topline data from AHFIRM trial expected in 2023"
02/06/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Form of Warrant (February 2023)",
"Form of Pre-Funded Warrant (February 2023)",
"Opinion of Orrick, Herrington & Sutcliffe LLP",
"Form of Securities Purchase Agreement",
"DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants CUPERTINO, Calif., February 3, 2023 / PRNewswire / — DURECT Corporation , a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of an aggregate of 1,700,000 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase 300,000 shares of common stock, and accompanying warrants to purchase up to 2,000,000 shares of common stock in a registered direct offering . The shares of common stock and ac..."
02/03/2023 8-K Quarterly results
12/20/2022 8-K Quarterly results
11/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "DURECT Announces 1-for-10 Reverse Stock Split CUPERTINO, Calif., November 28, 2022/PRNewswire/ -- DURECT Corporation , a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT’s board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022. Beginning with the opening of trading on December 6, 2022, the Company's common stock will trade on a split-adjusted basis. At a Special Meeting of Stockholders held on November 22, 2022, DURECT stockholders voted to approve a proposal authorizing the board of directors of the Company to amend the Company's certificate of incorporation to effect a..."
11/22/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
09/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery - DURECT recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone payment for first commercial sale of POSIMIR"
08/09/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/04/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/07/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
02/11/2022 8-K Quarterly results
12/22/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit royalties based on U.S. sales - - Innocoll granted exclusive development and commercialization rights to POSIMIR in the United States - DURECT to discuss agreement on Conference Call and Webcast Today at 8:30 a.m. ET"
12/14/2021 8-K Quarterly results
11/12/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis in the U.S."
11/10/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol in Severe Alcohol-Associated Hepatitis"
11/02/2021 8-K Quarterly results
Docs: "DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs -Earnings Call and Webcast Today, November 2nd at 4:30 p.m. ET -Expanded number of AHFIRM study sites -Opened first ex-US AHFIRM study sites"
07/29/2021 8-K Quarterly results
Docs: "DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs Earnings Call and Webcast Today, July 29 th at 4:30 p.m. ET"
06/25/2021 8-K/A Quarterly results
06/23/2021 8-K Quarterly results
06/16/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy